Cargando…

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

OBJECTIVE: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. PATIENTS AND METHODS: Overall 208 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Styczen, Hanna, Nagelmeier, Iris, Beissbarth, Tim, Nietert, Manuel, Homayounfar, Kia, Sprenger, Thilo, Boczek, Ute, Stanek, Kathrin, Kitz, Julia, Wolff, Hendrik A., Ghadimi, B. Michael, Middel, Peter, Liersch, Torsten, Rüschoff, Josef, Conradi, Lena-Christin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558136/
https://www.ncbi.nlm.nih.gov/pubmed/25915155
_version_ 1782388584250081280
author Styczen, Hanna
Nagelmeier, Iris
Beissbarth, Tim
Nietert, Manuel
Homayounfar, Kia
Sprenger, Thilo
Boczek, Ute
Stanek, Kathrin
Kitz, Julia
Wolff, Hendrik A.
Ghadimi, B. Michael
Middel, Peter
Liersch, Torsten
Rüschoff, Josef
Conradi, Lena-Christin
author_facet Styczen, Hanna
Nagelmeier, Iris
Beissbarth, Tim
Nietert, Manuel
Homayounfar, Kia
Sprenger, Thilo
Boczek, Ute
Stanek, Kathrin
Kitz, Julia
Wolff, Hendrik A.
Ghadimi, B. Michael
Middel, Peter
Liersch, Torsten
Rüschoff, Josef
Conradi, Lena-Christin
author_sort Styczen, Hanna
collection PubMed
description OBJECTIVE: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. PATIENTS AND METHODS: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months. RESULTS: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037). CONCLUSIONS: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.
format Online
Article
Text
id pubmed-4558136
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-45581362015-09-09 HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer Styczen, Hanna Nagelmeier, Iris Beissbarth, Tim Nietert, Manuel Homayounfar, Kia Sprenger, Thilo Boczek, Ute Stanek, Kathrin Kitz, Julia Wolff, Hendrik A. Ghadimi, B. Michael Middel, Peter Liersch, Torsten Rüschoff, Josef Conradi, Lena-Christin Oncotarget Research Paper OBJECTIVE: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. PATIENTS AND METHODS: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies (n = 29) or resection specimens (n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months. RESULTS: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status (p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 (p = 0.037). CONCLUSIONS: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches. Impact Journals LLC 2015-04-13 /pmc/articles/PMC4558136/ /pubmed/25915155 Text en Copyright: © 2015 Styczen et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Styczen, Hanna
Nagelmeier, Iris
Beissbarth, Tim
Nietert, Manuel
Homayounfar, Kia
Sprenger, Thilo
Boczek, Ute
Stanek, Kathrin
Kitz, Julia
Wolff, Hendrik A.
Ghadimi, B. Michael
Middel, Peter
Liersch, Torsten
Rüschoff, Josef
Conradi, Lena-Christin
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
title HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
title_full HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
title_fullStr HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
title_full_unstemmed HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
title_short HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
title_sort her-2 and her-3 expression in liver metastases of patients with colorectal cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558136/
https://www.ncbi.nlm.nih.gov/pubmed/25915155
work_keys_str_mv AT styczenhanna her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT nagelmeieriris her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT beissbarthtim her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT nietertmanuel her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT homayounfarkia her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT sprengerthilo her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT boczekute her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT stanekkathrin her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT kitzjulia her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT wolffhendrika her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT ghadimibmichael her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT middelpeter her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT lierschtorsten her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT ruschoffjosef her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer
AT conradilenachristin her2andher3expressioninlivermetastasesofpatientswithcolorectalcancer